jbp-485 and Disease-Models--Animal

The present study aimed to investigate the regulation of JBP485 on the expressions of renal organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp), which can accelerate the renal excretion of accumulated endogenous toxins to attenuate vancomycin-induced nephrotoxicity (VIN) in rats. Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate). However, JBP485 could reverse these effects and improved the pathological condition and morphology of rat kidney with a decrease in wet weight. Moreover, JBP485 decreased the number of apoptosis cells in TUNEL staining as well as reversed the decreased expression of B-cell lymphoma-2 (Bcl-2) and the increased expressions of Bcl-2-like protein 4 (Bax) and Caspase-3 in rat kidney. In addition, JBP485 also increased the level of superoxide dismutase (SOD) and decreased the level of malondialdehyde (MDA) in rat kidney. But JBP485 did not affect the plasma concentrations of vancomycin. In conclusion, the mechanism of VIN might be involved in, at least in part, suppressing the expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp, and JBP485 could attenuate VIN in rats.

Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Cytoprotection; Disease Models, Animal; Gene Expression Regulation; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 2; Oxidative Stress; Peptides, Cyclic; Rats, Wistar; Renal Elimination; Vancomycin

Dry eye syndrome (DES), a multifactorial disease of the tears and ocular surface, is one of the most common ocular disorders. Tear film contains ocular mucins and is essential for maintaining the homeostasis of the wet ocular surface. Since there are a limited number of clinical options for the treatment of DES, additional novel treatments are needed to improve the clinical results. In this study, we found that placental extract-derived dipeptide (JBP485) clearly promoted the expression and secretion of gel-forming mucin 5ac (Muc5ac) in rabbit conjunctival epithelium. JBP485 also elevated the expression level of cell surface-associated mucins (Muc1/4/16) in rabbit corneal epithelium. The Schirmer tear test results indicated that JBP485 induced tear secretion in the rabbit model. Moreover, JBP485 clinically improved corneal epithelial damage in a mouse dry eye model. Thus, our data indicate that JBP485 efficiently promoted mucin and aqueous tear secretion in rabbit ocular surface epithelium and has the potential to be used as a novel treatment for DES.

Topics: Animals; Cells, Cultured; Disease Models, Animal; Dry Eye Syndromes; Epithelium, Corneal; Galectin 3; Mice; Mucin 5AC; Mucin-1; Mucin-4; Peptides, Cyclic; Rabbits; Real-Time Polymerase Chain Reaction; Tears